Improved immunization practices reduce childhood hepatitis B infection in Tonga

Vaccine

Volumn 27, Issue 33, 2009, Pages 4462-4467

  Danielsson, Niklas ^a   Fakakovikaetau, Toakase ^a   Szegedi, Edit ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Birth dose; Children; Convenience testing; Elimination target; HBsAg; Hepatitis B vaccine

Indexed keywords

BCG VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; MEASLES VACCINE;

ARTICLE; BIRTHPLACE; BLOOD SAMPLING; BLOOD TRANSFUSION; BREAST FEEDING; CHILD; CHILDHOOD DISEASE; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; CROSS-SECTIONAL STUDY; DELIVERY; DIPHTHERIA; EDUCATIONAL STATUS; FEMALE; HEALTH CARE ACCESS; HEPATITIS B; HOSPITAL ADMISSION; HOSPITAL SERVICE; HUMAN; IMMUNIZATION; INFANT; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MEASLES; OUTCOME ASSESSMENT; PERTUSSIS; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; SEROLOGY; SOCIOECONOMICS; TETANUS; TONGA; TUBERCULOSIS; VIRUS TRANSMISSION;

CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION PROGRAMS; INFANT; MALE; PREVALENCE; TONGA;

EID: 67649338396     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.05.051     Document Type: Article

References (24)

1. Ruff TA. Temporary advisor WHO. Importance of hepatitis B birth dose; 2007. Microsoft Publisher Presentation.
2. WHO position paper on hepatitis B vaccines. Weekly Epidemiological Record 2004;79:253-64; 2007;255-62. (http://www.who.int/wer/2004/en/wer7928.pdf).
3. Goldstein S.T., Zhou F., Hadler S.C., Bell B.P., Mast E.E., and Margolis H.S. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 34 6 (2005 Dec) 1329-1339
4. Amin J., Law M.G., Bartlett M., Kaldor J.M., and Dore G.J. Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet 368 9539 (2006) 938-945
5. Iloeje U.H., Yang H.I., Jen C.L., et al. Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol 5 8 (2007) 921-931
6. Broderick A.L., and Jonas M.M. Hepatitis B in children. Semin Liver Dis 23 1 (2003) 59-68
7. Boxall E.H., Sira J., Standish R.A., et al. Natural history of hepatitis B in perinatally infected carriers. Arch Dis Child Fetal Neonatal Ed 89 5 (2004) F456-F460
8. Wainwright R.B., McMahon B.J., Bender T.R., et al. Prevalence of hepatitis B virus infection in Tonga: identifying high risk groups for immunization with hepatitis B vaccine. Int J Epidemiol 15 4 (1986) 567-571
9. Zuckerman A.J. Prevention of primary liver cancer by immunization. N Engl J Med 336 26 (1997) 1906-1907
10. Mansoor O.D., and Salama P. Should hepatitis B vaccine be used for infants?. Expert Rev Vaccines 6 1 (2007) 29-33
11. Clements C.J., Baoping Y., Crouch A., et al. Progress in the control of hepatitis B infection in the Western Pacific Region. Vaccine 24 12 (2006) 1975-1982
12. Ushijima H., Dairaku M., Honma H., et al. Incidence of antibodies against human immunodeficiency virus, human T-cell lymphotropic virus type 1, hepatitis B virus, hemorrhagic fever with renal syndrome virus and Chlamydia in Tonga and western Samoa. Jpn J Med Sci Biol 43 4 (1990) 101-109
13. World Health Organization. Second generation surveillance surveys of HIV, other STIs and risk behaviours in 6 Pacific Island countries 2004-2005. 2007.
14. Wilson N., Ruff T.A., Rana B.J., Leydon J., and Locarnini S. The effectiveness of the infant hepatitis B immunisation program in Fiji, Kiribati Tonga and Vanuatu. Vaccine 18 26 (2000) 3059-3066
15. Naing LWTRBN. Practical issues in calculating the sample size for prevalence studies. Arch Orofac Sci 2006;1:1-14.
16. Dean A.G., Dean J.A., Burton A.H., and Dicker R.C. Epi Info: a general-purpose microcomputer program for public health information systems. Am J Prev Med 7 3 (1991 May) 178-182
17. Marion S.A., Tomm P.M., Pi D.W., and Mathias R.G. Long-term follow-up of hepatitis B vaccine in infants of carrier mothers. Am J Epidemiol 140 8 (1994 Oct 15) 734-746
18. Lolekha S., Warachit B., Hirunyachote A., Bowonkiratikachorn P., West D.J., and Poerschke G. Protective efficacy of hepatitis B vaccine without HBIG in infants of HBeAg-positive carrier mothers in Thailand. Vaccine 20 31-32 (2002) 3739-3743
19. Poovorawan Y., Theamboonlers A., Vimolket T., et al. Impact of hepatitis B immunisation as part of the EPI. Vaccine 19 78 (2000 Nov) 943-949
20. Milne A., West D.J., Chinh D.V., Moyes C.D., and Poerschke G. Field evaluation of the efficacy and immunogenicity of recombinant hepatitis B vaccine without HBIG in newborn Vietnamese infants. J Med Virol 67 3 (2002 Jul) 327-333
21. Harpaz R., McMahon B.J., Margolis H.S., et al. Elimination of new chronic hepatitis B virus infections: results of the Alaska immunization program. J Infect Dis 181 2 (2000 Feb) 413-418
22. Rubin L., Hefer E., Dubnov Y., Warman S., and Rishpon S. An evaluation of the efficacy of the national immunization programme for hepatitis B. Public Health 121 7 (2007 Jul) 529-533
23. WHO Regional Office for the Western Pacific. Guidelines for the implementation of STI prevalence surveys. 2007.
24. Masters N. Hepatitis B transmission within families. Br J Gen Pract 41 348 (1991 Jul) 301